Ex vivo-expanded but not in vitro-induced human regulatory T cells are candidates for cell therapy in autoimmune diseases thanks to stable demethylation of the FOXP3 regulatory T cell-specific demethylated region

Journal of Immunology

Volumn 194, Issue 1, 2015, Pages 113-124

  Rossetti, Maura ^a,b   Spreafico, Roberto ^a,b   Saidin, Suzan ^b   Chua, Camillus ^b   Moshref, Maryam ^a   Leong, Jing Yao ^b   Tan, York Kiat ^c,d,e   Thumboo, Julian ^c,d,e   Van Loosdregt, Jorg ^a   Albani, Salvatore ^a,b  

^a BURNHAM INSTITUTE   (United States)

^b Singapore Health Services   (Singapore)

^c SINGAPORE GENERAL HOSPITAL   (Singapore)

^d DUKE NUS MEDICAL SCHOOL   (Singapore)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 35; RAPAMYCIN; RETINOIC ACID; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IL10 PROTEIN, HUMAN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, HUMAN; LYMPHOCYTE ANTIGEN RECEPTOR; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CELL EXPANSION; CELL STIMULATION; CELL SURFACE; CELL THERAPY; CELL VIABILITY; CELLULAR SECRETION; CLINICAL ARTICLE; CONTROLLED STUDY; DEMETHYLATION; EX VIVO STUDY; FEASIBILITY STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE STRUCTURE; MALE; MIDDLE AGED; PROTEIN EXPRESSION; PROTEIN SECRETION; REGULATORY T CELL SPECIFIC DEMETHYLATED REGION; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; ANIMAL; ARTHRITIS, RHEUMATOID; BIOLOGICAL THERAPY; CELL CULTURE; CELL PROLIFERATION; DNA METHYLATION; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; PROCEDURES; TRANSPLANTATION;

ADULT; AGED; ANIMALS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; CELLS, CULTURED; CTLA-4 ANTIGEN; DNA METHYLATION; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-10; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; RECEPTORS, ANTIGEN, T-CELL; SIROLIMUS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84919628900     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401145     Document Type: Article

References (56)

1. Josefowicz, S. Z., L. F. Lu, and A. Y. Rudensky. 2012. Regulatory T cells: Mechanisms of differentiation and function. Annu. Rev. Immunol. 30: 531-564.
2. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science 299: 1057-1061.
3. Williams, L. M., and A. Y. Rudensky. 2007. Maintenance of the Foxp3- dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8: 277-284.
4. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336.
5. Leguern, C. 2011. Regulatory T cells for tolerance therapy: Revisiting the concept. Crit. Rev. Immunol. 31: 189-207.
6. Rosenblum, M. D., I. K. Gratz, J. S. Paw, and A. K. Abbas. 2012. Treating human autoimmunity: Current practice and future prospects. Sci. Transl. Med. 4: 125sr121.
7. Valencia, X., C. Yarboro, G. Illei, and P. E. Lipsky. 2007. Deficient CD4+ CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J. Immunol. 178: 2579-2588.
8. Battaglia, M., A. Stabilini, and E. Tresoldi. 2012. Expanding human T regulatory cells with the mTOR-inhibitor rapamycin. Methods Mol. Biol. 821: 279-293.
9. Golovina, T. N., T. Mikheeva, T. M. Brusko, B. R. Blazar, J. A. Bluestone, and J. L. Riley. 2011. Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. PLoS One 6: E15868.
10. Hippen, K. L., S. C. Merkel, D. K. Schirm, C. M. Sieben, D. Sumstad, D. M. Kadidlo, D. H. McKenna, J. S. Bromberg, B. L. Levine, J. L. Riley, et al. 2011. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci. Transl. Med. 3: 83ra41.
11. Hippen, K. L., S. C. Merkel, D. K. Schirm, C. Nelson, N. C. Tennis, J. L. Riley, C. H. June, J. S. Miller, J. E. Wagner, and B. R. Blazar. 2011. Generation and large-scale expansion of human inducible regulatory T cells that suppress graftversus- host disease. Am. J. Transplant. 11: 1148-1157.
12. Wang, J., T. W. Huizinga, and R. E. Toes. 2009. De novo generation and enhanced suppression of human CD4+CD25+ regulatory T cells by retinoic acid. J. Immunol. 183: 4119-4126.
13. Ohkura, N., Y. Kitagawa, and S. Sakaguchi. 2013. Development and maintenance of regulatory T cells. Immunity 38: 414-423.
14. Allan, S. E., S. Q. Crome, N. K. Crellin, L. Passerini, T. S. Steiner, R. Bacchetta, M. G. Roncarolo, and M. K. Levings. 2007. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int. Immunol. 19: 345-354.
15. Wang, J., A. Ioan-Facsinay, E. I. van der Voort, T. W. Huizinga, and R. E. Toes. 2007. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 37: 129-138.
16. Hoffmann, P., T. J. Boeld, R. Eder, J. Huehn, S. Floess, G. Wieczorek, S. Olek, W. Dietmaier, R. Andreesen, and M. Edinger. 2009. Loss of FOXP3 expression in natural human CD4+CD25+ regulatory T cells upon repetitive in vitro stimulation. Eur. J. Immunol. 39: 1088-1097.
17. Ukena, S. N., M. Höpting, S. Velaga, P. Ivanyi, J. Grosse, U. Baron, A. Ganser, and A. Franzke. 2011. Isolation strategies of regulatory T cells for clinical trials: Phenotype, function, stability, and expansion capacity. Exp. Hematol. 39: 1152-1160.
18. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J. Exp. Med. 200: 277-285.
19. Lawson, C. A., A. K. Brown, V. Bejarano, S. H. Douglas, C. H. Burgoyne, A. S. Greenstein, A. W. Boylston, P. Emery, F. Ponchel, and J. D. Isaacs. 2006. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology 45: 1210-1217.
20. Venken, K., N. Hellings, T. Broekmans, K. Hensen, J. L. Rummens, and P. Stinissen. 2008. Natural naive CD4+CD25+CD127low regulatory T cell (Treg) development and function are disturbed in multiple sclerosis patients: Recovery of memory Treg homeostasis during disease progression. J. Immunol. 180: 6411-6420.
21. Buckner, J. H. 2010. Mechanisms of impaired regulation by CD4+CD25+ FOXP3+ regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849-859.
22. Dominguez-Villar, M., C. M. Baecher-Allan, and D. A. Hafler. 2011. Identification of T helper type 1-like, Foxp3+ regulatory T cells in human autoimmune disease. Nat. Med. 17: 673-675.
23. McClymont, S. A., A. L. Putnam, M. R. Lee, J. H. Esensten, W. Liu, M. A. Hulme, U. Hoffmuller, U. Baron, S. Olek, J. A. Bluestone, and T. M. Brusko. 2011. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J. Immunol. 186: 3918-3926.
24. Bailey-Bucktrout, S. L., M. Martinez-Llordella, X. Zhou, B. Anthony, W. Rosenthal, H. Luche, H. J. Fehling, and J. A. Bluestone. 2013. Self-Antigendriven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 39: 949-962.
25. Spreafico, R., M. Rossetti, T. van den Broek, N. J. Jansen, H. Zhang, M. Moshref, B. Prakken, J. van Loosdregt, F. van Wijk, and S. Albani. 2014. A sensitive protocol for FOXP3 epigenetic analysis in scarce human samples. Eur. J. Immunol. 44: 3141-3143.
26. Baron, U., S. Floess, G. Wieczorek, K. Baumann, A. Grutzkau, J. Dong, A. Thiel, T. J. Boeld, P. Hoffmann, M. Edinger, et al. 2007. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3+ conventional T cells. Eur. J. Immunol. 37: 2378-2389.
27. Nagar, M., H. Vernitsky, Y. Cohen, D. Dominissini, Y. Berkun, G. Rechavi, N. Amariglio, and I. Goldstein. 2008. Epigenetic inheritance of DNA methylation limits activation-induced expression of FOXP3 in conventional human CD252CD4+ T cells. Int. Immunol. 20: 1041-1055.
28. Stockis, J., W. Fink, V. Francois, T. Connerotte, C. de Smet, L. Knoops, P. van der Bruggen, T. Boon, P. G. Coulie, and S. Lucas. 2009. Comparison of stable human Treg and Th clones by transcriptional profiling. Eur. J. Immunol. 39: 869-882.
29. Miyara, M., Y. Yoshioka, A. Kitoh, T. Shima, K. Wing, A. Niwa, C. Parizot, C. Taflin, T. Heike, D. Valeyre, et al. 2009. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30: 899-911.
30. Floess, S., J. Freyer, C. Siewert, U. Baron, S. Olek, J. Polansky, K. Schlawe, H. D. Chang, T. Bopp, E. Schmitt, et al. 2007. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol. 5: E38.
31. Kim, H. P., and W. J. Leonard. 2007. CREB/ATF-dependent T cell receptorinduced FoxP3 gene expression: A role for DNA methylation. J. Exp. Med. 204: 1543-1551.
32. Lal, G., N. Zhang, W. van der Touw, Y. Ding, W. Ju, E. P. Bottinger, S. P. Reid, D. E. Levy, and J. S. Bromberg. 2009. Epigenetic regulation of Foxp3 expression in regulatory T cells by DNA methylation. J. Immunol. 182: 259-273.
33. Zheng, Y., S. Josefowicz, A. Chaudhry, X. P. Peng, K. Forbush, and A. Y. Rudensky. 2010. Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate. Nature 463: 808-812.
34. Polansky, J. K., L. Schreiber, C. Thelemann, L. Ludwig, M. Kruger, R. Baumgrass, S. Cording, S. Floess, A. Hamann, and J. Huehn. 2010. Methylation matters: Binding of Ets-1 to the demethylated Foxp3 gene contributes to the stabilization of Foxp3 expression in regulatory T cells. J. Mol. Med. 88: 1029-1040.
35. Ohkura, N., M. Hamaguchi, H. Morikawa, K. Sugimura, A. Tanaka, Y. Ito, M. Osaki, Y. Tanaka, R. Yamashita, N. Nakano, et al. 2012. T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. Immunity 37: 785-799.
36. Scotta, C., M. Esposito, H. Fazekasova, G. Fanelli, F. C. Edozie, N. Ali, F. Xiao, M. Peakman, B. Afzali, P. Sagoo, R. I. Lechler, and G. Lombardi. 2013. Differential effects of rapamycin and retinoic acid on expansion, stability and suppressive qualities of human CD4+CD25+FOXP3+ Treg subpopulations. Haematologica 98: 1291-1299.
37. Leslie, M. 2011. Immunology: Regulatory T cells get their chance to shine. Science 332: 1020-1021.
38. Brunstein, C. G., J. S. Miller, Q. Cao, D. H. McKenna, K. L. Hippen, J. Curtsinger, T. Defor, B. L. Levine, C. H. June, P. Rubinstein, et al. 2011. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: Safety profile and detection kinetics. Blood 117: 1061-1070.
39. Liu, W., A. L. Putnam, Z. Xu-Yu, G. L. Szot, M. R. Lee, S. Zhu, P. A. Gottlieb, P. Kapranov, T. R. Gingeras, B. Fazekas de St Groth, et al. 2006. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J. Exp. Med. 203: 1701-1711.
40. Marek-Trzonkowska, N., M. Mysliwiec, A. Dobyszuk, M. Grabowska, I. Techmanska, J. Juscinska, M. A. Wujtewicz, P. Witkowski, W. Mlynarski, A. Balcerska, et al. 2012. Administration of CD4+CD25highCD1272 regulatory T cells preserves b-cell function in type 1 diabetes in children. Diabetes Care 35: 1817-1820.
41. Zeiser, R., D. B. Leveson-Gower, E. A. Zambricki, N. Kambham, A. Beilhack, J. Loh, J. Z. Hou, and R. S. Negrin. 2008. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 111: 453-462.
42. Basu, S., T. Golovina, T. Mikheeva, C. H. June, and J. L. Riley. 2008. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J. Immunol. 180: 5794-5798.
43. Tresoldi, E., I. Dell'Albani, A. Stabilini, T. Jofra, A. Valle, N. Gagliani, A. Bondanza, M. G. Roncarolo, and M. Battaglia. 2011. Stability of human rapamycin-expanded CD4+CD25+ T regulatory cells. Haematologica 96: 1357-1365.
44. Selvaraj, R. K., and T. L. Geiger. 2007. A kinetic and dynamic analysis of Foxp3 induced in T cells by TGF-b. [Erratum in 2007 J. Immunol. 179: 1390]. J. Immunol. 179: 11 p following 1390.
45. Chen, Q., Y. C. Kim, A. Laurence, G. A. Punkosdy, and E. M. Shevach. 2011. IL-2 controls the stability of Foxp3 expression in TGF-b-induced Foxp3+ T cells in vivo. J. Immunol. 186: 6329-6337.
46. Beres, A., R. Komorowski, M. Mihara, and W. R. Drobyski. 2011. Instability of Foxp3 expression limits the ability of induced regulatory T cells to mitigate graft versus host disease. Clin. Cancer Res. 17: 3969-3983.
47. Tran, D. Q., H. Ramsey, and E. M. Shevach. 2007. Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-b dependent but does not confer a regulatory phenotype. Blood 110: 2983-2990.
48. Hoffmann, P., R. Eder, and M. Edinger. 2011. Polyclonal expansion of human CD4+CD25+ regulatory T cells. Methods Mol. Biol. 677: 15-30.
49. Von Boehmer, H., and C. Daniel. 2013. Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer. Nat. Rev. Drug Discov. 12: 51-63.
50. Daniel, C., K.Wennhold, H. J. Kim, and H. Von Boehmer. 2010. Enhancement of antigen-specific Treg vaccination in vivo. Proc. Natl. Acad. Sci. USA 107: 16246-16251.
51. Lange, C. M., T. Y. Tran, H. Farnik, S. Jungblut, T. Born, T. O. Wagner, and T. O. Hirche. 2010. Increased frequency of regulatory T cells and selection of highly potent CD62L+ cells during treatment of human lung transplant recipients with rapamycin. Transpl. Int. 23: 266-276.
52. Fernandez, D., E. Bonilla, N. Mirza, B. Niland, and A. Perl. 2006. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 54: 2983-2988.
53. Monti, P., M. Scirpoli, P. Maffi, L. Piemonti, A. Secchi, E. Bonifacio, M. G. Roncarolo, and M. Battaglia. 2008. Rapamycin monotherapy in patients with type 1 diabetes modifies CD4+CD25+FOXP3+ regulatory T-cells. Diabetes 57: 2341-2347.
54. Akimova, T., B. M. Kamath, J. W. Goebel, K. E. Meyers, E. B. Rand, A. Hawkins, M. H. Levine, J. C. Bucuvalas, and W. W. Hancock. 2012. Differing effects of rapamycin or calcineurin inhibitor on T-regulatory cells in pediatric liver and kidney transplant recipients. Am. J. Transplant. 12: 3449-3461.
55. Singh, K., N. Kozyr, L. Stempora, A. D. Kirk, C. P. Larsen, B. R. Blazar, and L. S. Kean. 2012. Regulatory T cells exhibit decreased proliferation but enhanced suppression after pulsing with sirolimus. Am. J. Transplant. 12: 1441-1457.
56. Desreumaux, P., A. Foussat, M. Allez, L. Beaugerie, X. Hebuterne, Y. Bouhnik, M. Nachury, V. Brun, H. Bastian, N. Belmonte, et al. 2012. Safety and efficacy of antigen-specific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology 143: 1207-1217 e1201-e1202.